{"id":"NCT01959035","sponsor":"H. Lundbeck A/S","briefTitle":"Aripiprazole Once-monthly in Patients With Schizophrenia","officialTitle":"Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2013-10-09","resultsPosted":"2016-05-16","lastUpdate":"2017-03-17"},"enrollment":88,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole once-monthly","otherNames":["Abilify MaintenaÂ®"]}],"arms":[{"label":"Aripiprazole once-monthly","type":"EXPERIMENTAL"}],"summary":"To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.","primaryOutcome":{"measure":"Safety and Tolerability","timeFrame":"Up to 24 weeks and 4-week safety follow up","effectByArm":[{"arm":"Aripiprazole Once-monthly","deltaMin":65,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003239-47/results"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":88},"commonTop":["Weight increased"]}}